Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biological markers in multiple sclerosis.

D Franciotta1

  • 1Laboratory of Neuroimmunology, IRCCS, Foundation Neurological Institute C. Mondino, University of Pavia, Italy. diego.franciotta@mondino.it

International MS Journal
|December 9, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improving the sensitivity of myelin oligodendrocyte glycoprotein-antibody testing: exclusive or predominant MOG-IgG3 seropositivity-a potential diagnostic pitfall in patients with MOG-EM/MOGAD.

Journal of neurology·2024
Same author

Thyroid function in the subacute phase of traumatic brain injury: a potential predictor of post-traumatic neurological and functional outcomes.

Journal of endocrinological investigation·2021
Same author

Subgroup comparison according to clinical phenotype and serostatus in autoimmune encephalitis: a multicenter retrospective study.

European journal of neurology·2019
Same author

Cerebrospinal fluid kappa and lambda free light chains in oligoclonal band-negative patients with suspected multiple sclerosis.

European journal of neurology·2019
Same author

Outcomes after single-cycle rituximab monotherapy in patients with anti-MAG polyneuropathy: A bi-center experience with an average follow-up of 11 years.

Journal of neuroimmunology·2019
Same author

"Limbic encephalitis with acute onset and Hu antibodies treated with rituximab: Paraneoplastic or non-paraneoplastic disorder?"

Clinical neurology and neurosurgery·2019

Identifying reliable biomarkers for multiple sclerosis (MS) is crucial for disease subtyping, monitoring inflammation, and assessing treatment response. Cerebrospinal fluid analysis is key to discovering these essential disease markers.

Area of Science:

  • Neuroscience
  • Immunology
  • Biomarker Discovery

Background:

  • Effective multiple sclerosis (MS) therapies are advancing, necessitating urgent identification of disease-related biomarkers.
  • Current lack of reliable biomarkers hinders understanding of MS etiology and pathogenesis.
  • Biomarkers are needed for disease subtyping, inflammation detection, axonal damage assessment, remyelination monitoring, and predicting therapy responses.

Purpose of the Study:

  • To highlight the urgent need for reliable biomarkers in multiple sclerosis (MS).
  • To emphasize the potential of new technologies in advancing MS understanding and biomarker identification.
  • To underscore the importance of cerebrospinal fluid analysis for biomarker discovery in MS.

Main Methods:

  • Review of current challenges and future directions in MS biomarker research.

Related Experiment Videos

  • Emphasis on the role of cerebrospinal fluid (CSF) analysis.
  • Exploration of new technologies for enhanced understanding of MS pathology.

    • Main Results:

    • Advances in MS treatments underscore the critical need for robust biomarkers.
    • Cerebrospinal fluid is identified as a primary source for pathological and reparative process markers.
    • New technologies offer promise for improved MS understanding and biomarker identification.

    Conclusions:

    • Reliable biomarkers are essential for personalized medicine approaches in multiple sclerosis.
    • Further research, particularly focusing on cerebrospinal fluid, is vital for biomarker discovery.
    • Technological advancements are expected to accelerate the identification of crucial MS markers.